Advanced Search

 

Study ID Status Title Patient Level Data
205341 Completed A Multicenter Post Marketing Surveillance Study to monitor the safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY conjugate vaccine(MenACWY-CRM) administered according to the prescribing information to healthy subjects from 2 months to 55 years of age in the Republic of South Korea.
205343 Recruiting Immunogenicity, reactogenicity and safety of two formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) in healthy adults 18 to 40 years of age
205352 Completed A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 through 55 years of age, approximately 4-6 years after primary ACWY vaccination
205369 Completed Impact of rotavirus vaccination on hospital pressures at a large paediatric hospital in the UK: an ecological study
205421 Completed A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subjects.
205431 Withdrawn Determination of SPF, before and after immersion in water, for a cosmetic product at minimum of 3 subjects.
205432 Withdrawn Determination of SPF, before and after immersion in water, for a cosmetic product at minimum of 3 subjects
205433 Withdrawn Determination of SPF, before and after immersion in water, for a cosmetic product at minimum of 3 subjects.
205434 Withdrawn A comparative, open-label, randomized, and controlled clinical efficacy trial for preview evaluation of the skin oiliness control for three cosmetics products
205494 Completed A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis Study Listed on ClinicalStudyDataRequest.com
205496 Completed A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).
205512 Recruiting Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero®) vaccination in routine UK care
205514 Recruiting Post-licensure observational effectiveness study of meningococcal B vaccine 4CMenB (Bexsero®) vaccination
205523 Completed Feasibility study for identifying a sero-correlate of protection against invasive Group B Streptococcus disease in newborns and young infants aged less ≤90 days
205531 Completed MENVEO® pregnancy registry: an observational study on the safety of MENVEO exposure in pregnant women and their offspring
205533 Recruiting 4CMenB pregnancy registry: an observational study of the safety of 4CMenB exposure in pregnant women and their offspring.
205534 Completed Post-licensure observational safety surveillance study of quadrivalent meningococcal ACWY conjugate vaccine MenACWY-CRM (MENVEO®) in children 2 months through 23 months of age.
205540 Completed A randomised, double-blind, placebo-controlled, parallel group, 8-week treatment study to investigate the safety, pharmacodynamics, and effect of the TLR7 agonist, GSK2245035, on the allergen-induced asthmatic response in subjects with mild allergic asthma
205613 Completed A Phase 2b Open-Label Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 years After the last Meningococcal Vaccination in Study V102_15 (NCT02212457) and the Response to a Booster dose of GSK MenABCWY or Meningococcal Serogroup B Vaccines, in Healthy Adolescents
205626 Recruiting Efficacy, safety and immunogenicity of GVGH Shigella sonnei vaccine (1790GAHB) in a human challenge study of healthy non-immune adults
205633 Completed Severe Asthma: Characterizing Patient Impacts of Frequent/Chronic Use of Oral Corticosteroids
205634 Completed A phase IV, open label, single-center extension study, to evaluate the long-term persistence of immune responses after post-exposure prophylaxis with purified chicken-embryo cell rabies Vaccine in Chinese children
205636 Completed A Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Local Nasal Tolerability and Safety of 1146A in Healthy Adult Subjects
205637 Withdrawn An open-label, multicenter, randomized, parallel group, single-dose study to assess the short term efficacy and safety of paracetamol 500 mg + phenylephrine HCl 10 mg + pheniramine maleate 20 mg + vitamin C 200 mg powder for oral solution in subjects with symptoms of an upper respiratory tract infection
205638 Withdrawn An open-label, multicenter, randomized, parallel group, single-dose study to assess the short term efficacy and safety of paracetamol 500 mg + phenylephrine HCl 10 mg + vitamin C 200 mg powder for oral solution in subjects with symptoms of an upper respiratory tract infection

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.